Hormonal contraceptive methods for women at high risk of HIV and living with HIV 2014 guidance statement

Given the public health importance of this topic, and at the encouragement of the GDG, the World Health Organization is issuing its contraceptive eligibility guidance for women at high risk of HIV and women living with HIV in advance of the entire guideline revision. It is anticipated that the revis...

Full description

Bibliographic Details
Corporate Authors: World Health Organization, World Health Organization Reproductive Health and Research
Format: eBook
Language:English
Published: Geneva, Switzerland World Health Organization 2014, [2014]
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 03190nam a2200313 u 4500
001 EB002001424
003 EBX01000000000000001164325
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
245 0 0 |a Hormonal contraceptive methods for women at high risk of HIV and living with HIV  |h Elektronische Ressource  |b 2014 guidance statement 
260 |a Geneva, Switzerland  |b World Health Organization  |c 2014, [2014] 
300 |a 1 PDF file (13 pages) 
505 0 |a Includes bibliographical references 
653 |a Contraindications 
653 |a Contraceptives, Postcoital, Hormonal 
653 |a HIV Infections / transmission 
653 |a HIV Infections / prevention & control 
653 |a Contraceptives, Oral, Hormonal 
653 |a Evidence-Based Medicine / standards 
653 |a Risk Assessment 
710 2 |a World Health Organization 
710 2 |a World Health Organization  |b Reproductive Health and Research 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
500 |a Title from PDF caption. - "WHO/RHR/14.24." 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK299589  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a Given the public health importance of this topic, and at the encouragement of the GDG, the World Health Organization is issuing its contraceptive eligibility guidance for women at high risk of HIV and women living with HIV in advance of the entire guideline revision. It is anticipated that the revised fifth edition of the MEC will be completed in 2015. Recommendations for hormonal contraceptive use are provided for: women at high risk of HIV infection; women living with asymptomatic or mild HIV clinical disease (WHO stage 1 or 2); women living with severe or advanced HIV clinical disease (WHO stage 3 or 4); women living with HIV using antiretroviral therapy (ART). Hormonal contraceptives include: combined oral contraceptive pills (COCs), combined injectable contraceptives (CICs), combined contraceptive patches and rings, progestogen-only injectables (depot medroxyprogesterone acetate [DMPA] and norethisterone enantate [NET-EN]), progestogen-only pills (POPs), levonorgestrel (LNG) and etonogestrel (ETG) implants, and levonorgestrel-releasing IUDs (LNG-IUDs). These are all effective or highly effective methods of pregnancy prevention. These contraceptive methods alleviate overall pregnancy- related morbidity and mortality, improve infant and child health, and reduce vertical transmission of HIV among women living with HIV who wish to prevent pregnancy. For women at high risk of HIV, living with HIV, or taking antiretroviral medicines (ARVs), consideration must be given to the relationship between the use of hormonal contraceptive methods and HIV-related risks. Additionally, women at high risk of HIV or living with HIV may require information about and access to HIV preventive measures. Such measures include, among others, condoms (male or female), voluntary male circumcision, voluntary HIV counselling and testing, and antiretroviral treatment (ART) for HIV- positive partners in serodiscordant partnerships